Researchers developed a machine learning tool called OBSCORE to predict the risk of obesity-related complications using data from approximately 200,000 individuals. Validated in the SURMOUNT-1 trial, the study showed that tirzepatide effectively reduced these predicted risks across different baseline risk groups, regardless of the patient's initial risk score.